Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Histone deacetylase inhibitors synergizes with catalytic inhibitors of EZH2 to exhibit antitumor activity in small cell carcinoma of the ovary, hypercalcemic type

Autor: Wang, Yemin, Chen, Shary Yuting, Colborne, Shane, Lambert, Galen, Shin, Chae Young, Santos, Nancy Dos, Orlando, Krystal A, Lang, Jessica D, Hendricks, William PD, Bally, Marcel B, Karnezis, Anthony N, Hass, Ralf, Underhill, T Michael, Morin, Gregg B, Trent, Jeffrey M, Weissman, Bernard E, Huntsman, David G

Publikováno v: Molecular cancer therapeutics, vol 17, iss 12

Small cell carcinoma of the ovary, hypercalcemic type (SCCOHT) is a rare but extremely lethal malignancy that mainly impacts young women. SCCOHT is characterized by a diploid genome with loss of SMARCA4 and lack of SMARCA2 expression, two mutually ex

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5f9b88764a9871d432cdb81a6441b67e

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

The histone methyltransferase EZH2 is a therapeutic target in small cell carcinoma of the ovary, hypercalcaemic type.

Autor: Wang Y; Department of Pathology and Laboratory Medicine, University of British Columbia and Department of Molecular Oncology, British Columbia Cancer Research Centre, Vancouver, BC, Canada., Chen SY; Department of Pathology and Laboratory Medicine, University of British Columbia and Department of Molecular Oncology, British Columbia Cancer Research Centre, Vancouver, BC, Canada., Karnezis AN; Department of Pathology and Laboratory Medicine, University of British Columbia and Department of Molecular Oncology, British Columbia Cancer Research Centre, Vancouver, BC, Canada., Colborne S; Michael Smith Genome Science Centre, British Columbia Cancer Agency, Vancouver, BC, Canada., Santos ND; Department of Experimental Therapeutics, British Columbia Cancer Research Centre, Vancouver, BC, Canada., Lang JD; Division of Integrated Cancer Genomics, Translational Genomics Research Institute (TGen), Phoenix, AZ, USA., Hendricks WP; Division of Integrated Cancer Genomics, Translational Genomics Research Institute (TGen), Phoenix, AZ, USA., Orlando KA; Department of Pathology and Laboratory Medicine and Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC, USA., Yap D; Department of Pathology and Laboratory Medicine, University of British Columbia and Department of Molecular Oncology, British Columbia Cancer Research Centre, Vancouver, BC, Canada., Kommoss F; Department of Pathology and Laboratory Medicine, University of British Columbia and Department of Molecular Oncology, British Columbia Cancer Research Centre, Vancouver, BC, Canada., Bally MB; Department of Experimental Therapeutics, British Columbia Cancer Research Centre, Vancouver, BC, Canada., Morin GB; Department of Experimental Therapeutics, British Columbia Cancer Research Centre, Vancouver, BC, Canada.; Department of Medical Genetics, University of British Columbia, Vancouver, BC, Canada., Trent JM; Division of Integrated Cancer Genomics, Translational Genomics Research Institute (TGen), Phoenix, AZ, USA., Weissman BE; Department of Pathology and Laboratory Medicine and Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC, USA., Huntsman DG; Department of Pathology and Laboratory Medicine, University of British Columbia and Department of Molecular Oncology, British Columbia Cancer Research Centre, Vancouver, BC, Canada.; Department of Obstetrics and Gynaecology, University of British Columbia, Vancouver, BC, Canada.

Publikováno v: The Journal of pathology [J Pathol] 2017 Jul; Vol. 242 (3), pp. 371-383. Date of Electronic Publication: 2017 Jun 02.